In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not reduce recurrent stroke vs aspirin in the ARCADIA trial.
A multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to new research.
Apixaban Matches Aspirin in Preventing Certain Strokes miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.